Single-dose dye imaging for lung cancer surgery
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a single dose of a special dye (LS301-IT) that helps surgeons see lung cancer cells more clearly during surgery. It aims to make lung cancer removal more precise and complete.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with or are strongly suspected to have lung cancer (non-small cell type).
- You are planning to have surgery to remove a lung tumor through a small camera (thoracoscopy).
- You are willing to use birth control (if you could become pregnant) or are not able to have children.
- You are not allergic to indocyanine green (a dye used in some imaging tests).
- You do not have serious kidney, liver, or heart problems that might make the surgery risky.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a special imaging drug (18F-Alfatide) given as a shot before a PET/CT scan. It helps doctors see if non-small cell lung cancer has spread to lymph nodes, which could help plan your surgery.
This trial tests a dye that makes lung cancer cells glow during surgery, helping surgeons remove more of the tumor. It's for people who are already scheduled for lung cancer surgery.
This trial studies a dye-based technique (using indocyanine green) to help surgeons identify lung segments during a lung cancer operation (segmentectomy). The goal is to improve how accurately and safely surgeons remove the affected part of the lung.
This trial tests a new way to plan and guide lung cancer surgery using a special dye that shows the tumor area during the operation. It may help surgeons remove the cancer more accurately while targeting only a small section of lung for certain early-stage patients.
This trial tests a special imaging drug (IRDye800CW-nimotuzumab) that may help surgeons better see lung cancer tissue during planned lung surgery. Phase 1/2 looks mainly at safety and how well the imaging works to guide the operation.
This trial tests a dye called abenacianine (VGT-309) that may help surgeons see cancer more clearly during lung surgery. It looks at whether the dye is safe and effective for identifying cancer in people having surgery to remove a lung lesion or mass.
Hear when a new Non Small Cell Lung Cancer (NSCLC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.